|
Market Closed -
Australian S.E.
11:40:27 04/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.3700 AUD | +2.78% |
|
+0.68% | -43.08% |
| 31/08 | Recce Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 31/08 | Recce Pharmaceuticals Ltd Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 11Cr 7.99Cr 6.87Cr 6.47Cr 5.91Cr 11Cr 754.1Cr 76Cr 30Cr 386.9Cr 30Cr 29Cr 1.25TCr | P/E 2027 * |
-4.35x | P/E 2028 * | 3.33x |
|---|---|---|---|---|---|
| Enterprise Value | 14Cr 9.79Cr 8.42Cr 7.92Cr 7.24Cr 14Cr 923.99Cr 94Cr 36Cr 474.07Cr 37Cr 36Cr 1.53TCr | EV / Sales 2027 * |
10.9x | EV / Sales 2028 * | 1.15x |
| Free-Float |
62.73% | Yield 2027 * |
-
| Yield 2028 * | - |
Australian S.E.AUD
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| RCE | Delayed | |
Deutsche Boerse AG
| R9Q | Delayed | |
|
Börse Stuttgart
| R9Q | Delayed | |
|
Boerse Muenchen
| R9Q | Real-time | |
|
Tradegate
| R9Q | Real-time |
| 1 day | +2.78% | ||
| 1 week | +0.68% | ||
| Current month | -1.33% | ||
| 1 month | -1.33% | ||
| 3 months | -29.52% | ||
| 6 months | -17.78% | ||
| Current year | -43.08% |
| 1 week | 0.36 |  | 0.38 |
| 1 month | 0.36 | | 0.38 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.73 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/07/26 | Buy | Chief Executive Officer | 25,000 | 0.0083% | ||
| 31/07/26 | Buy | Director | 75,000 | 0.0250% | ||
| 31/07/26 | Buy | Director | 37,500 | 0.0125% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.78% | +0.68% | -15.91% | -49.32% | 7.99Cr | |
| -0.88% | -2.15% | +54.71% | +106.31% | 1,02400Cr | |
| -1.15% | +2.68% | +53.97% | +71.50% | 66TCr | |
| -1.44% | +0.38% | +20.40% | +73.05% | 45TCr | |
| +0.14% | -0.47% | +29.49% | +38.56% | 35TCr | |
| -1.33% | +4.72% | +24.69% | +45.55% | 30TCr | |
| -1.15% | +0.30% | -1.49% | +12.31% | 25TCr | |
| -1.55% | +1.11% | +56.10% | +70.32% | 24TCr | |
| -0.88% | +1.15% | -17.09% | -54.39% | 21TCr | |
| -0.15% | +3.65% | +33.90% | +96.99% | 19TCr | |
| Average | -0.61% | +1.05% | +23.88% | +41.09% | 36.78TCr | |
| Weighted average by Cap. | -1.10% | +0.55% | +36.62% | +66.22% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 1.25Cr 90.07L 77.51L 72.92L 66.61L 1.25Cr 85Cr 8.62Cr 3.34Cr 44Cr 3.38Cr 3.31Cr 140.56Cr | 5.43Cr 3.91Cr 3.37Cr 3.17Cr 2.89Cr 5.42Cr 369.55Cr 37Cr 15Cr 189.6Cr 15Cr 14Cr 610.82Cr |
| Net income | -2.51Cr -1.81Cr -1.56Cr -1.46Cr -1.34Cr -2.5Cr -170.81Cr -17Cr -6.72Cr -88Cr -6.79Cr -6.65Cr -282.33Cr | 3.34Cr 2.41Cr 2.07Cr 1.95Cr 1.78Cr 3.33Cr 227.31Cr 23Cr 8.94Cr 116.63Cr 9.04Cr 8.84Cr 375.72Cr |
| Net Debt | 2.5Cr 1.8Cr 1.55Cr 1.46Cr 1.33Cr 2.49Cr 169.89Cr 17Cr 6.68Cr 87Cr 6.76Cr 6.61Cr 280.81Cr | -4.81Cr -3.47Cr -2.98Cr -2.81Cr -2.56Cr -4.8Cr -327.36Cr -33Cr -13Cr -167.96Cr -13Cr -13Cr -541.08Cr |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | A$0.3700 | +2.78% | 75,875 |
| 03/26/03 | A$0.3600 | 0.00% | 27,753 |
| 02/26/02 | A$0.3600 | 0.00% | 41,259 |
| 01/26/01 | A$0.3600 | -4.00% | 1,30,690 |
| 31/26/31 | A$0.3750 | +2.04% | 55,429 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
